A Phase 1/2 interventional study of Febuxostat in Tumor Lysis Syndrome, sponsored by Menarini Group. Terminated at 17 sites in 4 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Menarini Group · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6\<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect in terms of serum uric acid levels.
In the FLORET study it is planned to enroll 3 groups of patients in order to receive oral administration (film-coated tablets) of two different dose levels of febuxostat: children (from 6 to less than 12 years of age) will receive two different dose levels respectively; adolescents (from 12 to less than 18 years of age) will receive 80 and 120 mg/day respectively and adults (equal or major than 18 years of age) will receive 120 mg/day. The two dose levels for children and adolescents groups were to be sequentially administered, whereas the groups that will receive the first dose levels will simultaneously start the treatment at the study beginning. The individual treatment duration will be of 7 to 9 days, according to chemotherapy duration, as per Investigator's judgement.
20 studies on the registry are indexed under Tumor Lysis Syndrome; 1 is open to participants now.
This study's enrollment of 30 is below the median of 55 across 13 interventional studies indexed under Tumor Lysis Syndrome.
Browse Tumor Lysis Syndrome studies →Menarini Group is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
male and female children of 6 to less than 12 years of age, adolescents of 12 to less than 18 years of age and adults from 18 years:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
Drug: Febuxostat
Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
Drug: Febuxostat
Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
Drug: Febuxostat
Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
Drug: Febuxostat
Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
Drug: Febuxostat
Intervention is orally administered to patients in this arm.
Pharmacokinetic (PK) Parameter: Apparent Clearance (CL/F)
Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
Time frame: 7 days
PK Parameter: Apparent Volume of Distribution (Vd/F)
Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
Time frame: 7 days
PK Parameter: Absorption Rate Constant (Ka)
Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
Time frame: 7 days
PK Parameter: Area Under Curve (AUC)
AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
Time frame: 7 days
PK Parameter: Maximum Plasma Concentration (Cmax)
Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
Time frame: 7 days
PK Parameter: Tmax
Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
Time frame: 7 days
Pharmacodynamic (PD) Parameter: Area Under the Curve of Serum Uric Acid (sUA)
Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)
Time frame: 8 days
Assessment of Laboratory Tumor Lysis Syndrome (LTLS)
Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.
Time frame: 7 days
Assessment of Clinical Tumor Lysis Syndrome (CTLS)
Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.
Time frame: 7 days
Assessment of Treatment Emergent Signs and Symptoms (TESS)
Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.
Time frame: Estimated maximum time frame: 27 days
Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)
Number of participants affected by TESS from Screening Visit to End of Study Visit.
Time frame: Estimated maximum time frame: 27 days
Performance Status (PS) Evaluation
Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).
Time frame: Estimated maximum time frame: 27 days
The first patient was screened and enrolled on 27 Feb 2017. The last patient completed the study on 16 Jul 2018. The study was conducted at 17 sites in 4 European countries.
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults |
|---|---|---|---|---|---|
| Started | 3 | 0 | 3 | 0 | 24 |
| Completed | 3 | 0 | 3 | 0 | 24 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults |
|---|---|---|---|---|---|
| Started | 3 | 0 | 3 | 0 | 24 |
| Completed | 2 | 0 | 3 | 0 | 23 |
| Not completed | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
No measurements were reported for this outcome.
Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
No measurements were reported for this outcome.
Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
No measurements were reported for this outcome.
AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
No measurements were reported for this outcome.
Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
No measurements were reported for this outcome.
Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)
No measurements were reported for this outcome.
Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)
No measurements were reported for this outcome.
Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.
No measurements were reported for this outcome.
Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.
No measurements were reported for this outcome.
Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.
| Events | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults |
|---|---|---|---|---|---|
| TESS | 50 | — | 21 | — | 70 |
| TESS grade >/=3 | 11 | — | 2 | — | 20 |
| Serious TESS | 1 | — | 0 | — | 7 |
| Related TESS | 4 | — | 0 | — | 0 |
| Related TESS grade >/=3 | 2 | — | 0 | — | 0 |
| Related TESS/Drug Withdrawn | 2 | — | 0 | — | 0 |
Number of participants affected by TESS from Screening Visit to End of Study Visit.
| participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults |
|---|---|---|---|---|---|
| Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS) | 3 | — | 3 | — | 20 |
Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).
No measurements were reported for this outcome.
Collected over Adverse events were collected over the entire duration of a patient's study participation, i.e. approximately 3 weeks. In addition, if after the end of the study the Investigator became aware of any AEs or follow-up in AEs already recorded, this information could be recorded in the eCRF until it was available.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 2 | — | — | — |
| Cohort 3 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 4 | — | — | — |
| Adults | 0/24 (0%) | 5/24 (20.8%) | 20/24 (83.3%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults |
|---|---|---|---|---|---|
| Septioc shockInfections and infestations | 1/3 | — | 0/3 | — | 1/24 |
| Enterobacter test positivInvestigations | 0/3 | — | 0/3 | — | 1/24 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | — | 0/3 | — | 1/24 |
| Mucosal inflammationGeneral disorders | 0/3 | — | 0/3 | — | 1/24 |
| Abdominal painGastrointestinal disorders | 0/3 | — | 0/3 | — | 1/24 |
| ProctitisGastrointestinal disorders | 0/3 | — | 0/3 | — | 1/24 |
| Staphylococcal infectionInfections and infestations | 0/3 | — | 0/3 | — | 1/24 |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/3 | — | 3/3 | — | 4/24 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | — | 0/3 | — | 4/24 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/3 | — | 0/3 | — | 1/24 |
| Abdominal painGastrointestinal disorders | 2/3 | — | 0/3 | — | 4/24 |
| VomitingGastrointestinal disorders | 2/3 | — | 0/3 | — | 2/24 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/3 | — | 2/3 | — | 1/24 |
| Hot flushVascular disorders | 0/3 | — | 1/3 | — | 0/24 |
| AstheniaGeneral disorders | 1/3 | — | 1/3 | — | 0/24 |
| InflammationGeneral disorders | 1/3 | — | 0/3 | — | 0/24 |
| Oedema peripheralGeneral disorders | 1/3 | — | 0/3 | — | 0/24 |
DAY 1 before first febuxostat dosing.
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults | Total |
|---|---|---|---|---|---|---|
| <=18 years | 3 | 0 | 3 | 0 | 0 | 6 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 14 | 14 |
| >=65 years | 0 | 0 | 0 | 0 | 10 | 10 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults | Total |
|---|---|---|---|---|---|---|
| Mean | 7.33 ± 1.528 | — | 14.00 ± 1.000 | — | 60.21 ± 15.376 | 50.30 ± 24.419 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 0 | 11 | 14 |
| Male | 2 | 0 | 1 | 0 | 13 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 3 | 0 | 2 | 0 | 24 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 0 | 2 | 0 | 23 | 28 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults | Total |
|---|---|---|---|---|---|---|
| Hungary | 0 | — | 0 | — | 8 | 8 |
| Italy | 3 | — | 3 | — | 5 | 11 |
| Bulgaria | 0 | — | 0 | — | 0 | 0 |
| Spain | 0 | — | 0 | — | 11 | 11 |
| Weight(kg) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Adults | Total |
|---|---|---|---|---|---|---|
| Mean | 26.13 ± 2.043 | — | 60.47 ± 19.747 | — | 75.60 ± 15.469 | 68.92 ± 21.369 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Jul 2018, 16 months.
Results were first posted in Jun 2021, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat